149 related articles for article (PubMed ID: 21516080)
1. Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation.
Langer R; Rauser S; Feith M; Nährig JM; Feuchtinger A; Friess H; Höfler H; Walch A
Mod Pathol; 2011 Jul; 24(7):908-16. PubMed ID: 21516080
[TBL] [Abstract][Full Text] [Related]
2. HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma.
Hu Y; Bandla S; Godfrey TE; Tan D; Luketich JD; Pennathur A; Qiu X; Hicks DG; Peters JH; Zhou Z
Mod Pathol; 2011 Jul; 24(7):899-907. PubMed ID: 21460800
[TBL] [Abstract][Full Text] [Related]
3. Human epidermal growth factor receptor-2 in oesophageal cancers: an observational study.
Al-Momani H; Barnes R; El-Hadi A; Shah R; Lewis WG; Edwards P
World J Gastroenterol; 2012 Nov; 18(44):6447-51; discussion p.6450. PubMed ID: 23197890
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the HER2 amplification status in oesophageal adenocarcinoma by conventional and automated FISH: a tissue microarray study.
Prins MJ; Ruurda JP; van Diest PJ; van Hillegersberg R; ten Kate FJ
J Clin Pathol; 2014 Jan; 67(1):26-32. PubMed ID: 24043715
[TBL] [Abstract][Full Text] [Related]
5. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
Plum PS; Gebauer F; Krämer M; Alakus H; Berlth F; Chon SH; Schiffmann L; Zander T; Büttner R; Hölscher AH; Bruns CJ; Quaas A; Loeser H
BMC Cancer; 2019 Jan; 19(1):38. PubMed ID: 30621632
[TBL] [Abstract][Full Text] [Related]
6. Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma.
Gruver AM; Peerwani Z; Tubbs RR
J Clin Pathol; 2010 Mar; 63(3):210-9. PubMed ID: 20203220
[TBL] [Abstract][Full Text] [Related]
7. Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma.
König AM; Reeh M; Dancau AM; Rathjens M; Gros S; Uzunoglu FG; Bockhorn M; Simon R; Sauter G; Marx A; Izbicki JR
Anticancer Res; 2013 Nov; 33(11):4975-82. PubMed ID: 24222138
[TBL] [Abstract][Full Text] [Related]
8. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH).
Boers JE; Meeuwissen H; Methorst N
Histopathology; 2011 Feb; 58(3):383-94. PubMed ID: 21323962
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas.
Cho EY; Park K; Do I; Cho J; Kim J; Lee J; Kim S; Kim KM; Sohn TS; Kang WK; Kim S
Mod Pathol; 2013 May; 26(5):677-84. PubMed ID: 23238628
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung.
Grob TJ; Kannengiesser I; Tsourlakis MC; Atanackovic D; Koenig AM; Vashist YK; Klose H; Marx AH; Koops S; Simon R; Izbicki JR; Bokemeyer C; Sauter G; Wilczak W
Mod Pathol; 2012 Dec; 25(12):1566-73. PubMed ID: 22899293
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral heterogeneous amplification of ERBB2 and subclonal genetic diversity in gastric cancers revealed by multiple ligation-dependent probe amplification and fluorescence in situ hybridization.
Tajiri R; Ooi A; Fujimura T; Dobashi Y; Oyama T; Nakamura R; Ikeda H
Hum Pathol; 2014 Apr; 45(4):725-34. PubMed ID: 24491355
[TBL] [Abstract][Full Text] [Related]
12. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas.
Yoon HH; Shi Q; Sukov WR; Wiktor AE; Khan M; Sattler CA; Grothey A; Wu TT; Diasio RB; Jenkins RB; Sinicrope FA
Clin Cancer Res; 2012 Jan; 18(2):546-54. PubMed ID: 22252257
[TBL] [Abstract][Full Text] [Related]
13. EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus.
Birkman EM; Ålgars A; Lintunen M; Ristamäki R; Sundström J; Carpén O
BMC Cancer; 2016 Jul; 16():406. PubMed ID: 27387915
[TBL] [Abstract][Full Text] [Related]
14. PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer.
Ni R; Mulligan AM; Have C; O'Malley FP
Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):316-24. PubMed ID: 17721278
[TBL] [Abstract][Full Text] [Related]
15. Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival.
Thompson SK; Sullivan TR; Davies R; Ruszkiewicz AR
Ann Surg Oncol; 2011 Jul; 18(7):2010-7. PubMed ID: 21267790
[TBL] [Abstract][Full Text] [Related]
16. FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation.
Betts G; Valentine H; Pritchard S; Swindell R; Williams V; Morgan S; Griffiths EA; Welch I; West C; Womack C
Virchows Arch; 2014 Feb; 464(2):145-56. PubMed ID: 24306956
[TBL] [Abstract][Full Text] [Related]
17. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients.
Barros-Silva JD; Leitão D; Afonso L; Vieira J; Dinis-Ribeiro M; Fragoso M; Bento MJ; Santos L; Ferreira P; Rêgo S; Brandão C; Carneiro F; Lopes C; Schmitt F; Teixeira MR
Br J Cancer; 2009 Feb; 100(3):487-93. PubMed ID: 19156142
[TBL] [Abstract][Full Text] [Related]
18. Alterations of the CCND1 and HER-2/neu (ERBB2) proteins in esophageal and gastric cancers.
Bizari L; Borim AA; Leite KR; Gonçalves Fde T; Cury PM; Tajara EH; Silva AE
Cancer Genet Cytogenet; 2006 Feb; 165(1):41-50. PubMed ID: 16490596
[TBL] [Abstract][Full Text] [Related]
19. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment.
Kunz PL; Mojtahed A; Fisher GA; Ford JM; Chang DT; Balise RR; Bangs CD; Cherry AM; Pai RK
Appl Immunohistochem Mol Morphol; 2012 Jan; 20(1):13-24. PubMed ID: 21617522
[TBL] [Abstract][Full Text] [Related]
20. HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib.
Press MF; Ellis CE; Gagnon RC; Grob TJ; Buyse M; Villalobos I; Liang Z; Wu S; Bang YJ; Qin SK; Chung HC; Xu J; Park JO; Jeziorski K; Afenjar K; Ma Y; Estrada MC; Robinson DM; Scherer SJ; Sauter G; Hecht JR; Slamon DJ
Mol Cancer Ther; 2017 Jan; 16(1):228-238. PubMed ID: 27811012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
